A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Ilodecakin (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Fluorouracil; Folinic acid; Gemcitabine; Nivolumab; Oxaliplatin; Paclitaxel; Pazopanib; Pembrolizumab
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms IVY
- Sponsors Eli Lilly and Company
- 23 Jan 2024 Planned End Date changed from 17 Nov 2023 to 25 Aug 2024.
- 15 Nov 2022 Planned End Date changed from 15 Nov 2022 to 17 Nov 2023.
- 02 Sep 2021 Planned End Date changed from 15 Nov 2021 to 15 Nov 2022.